SCHEMBL3926072

SCHEMBL3926072

O=C(O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.66
PTPN1 P18031 2/20 0.44
MRGPRX4 Q96LA9 2/20 0.43
WDR5 P61964 1/20 0.43
MAOB P27338 3/20 0.43
PPARA Q07869 3/20 0.43
PPARG P37231 2/20 0.43
RXRA P19793 2/20 0.43
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43
TRPV1 Q8NER1 1/20 0.42
LDHA P00338 1/20 0.42
DRD4 P21917 1/20 0.42
P2RX1 P51575 1/20 0.42
P2RX3 P56373 1/20 0.42
P2RX4 Q99571 1/20 0.42
P2RX7 Q99572 1/20 0.42
PTGER1 P34995 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3934321 0.87 CXCR2 (0.66) CXCR2MAOBTRPV1DRD4P2RX1
SCHEMBL1681386 0.87 WDR5 (0.53) CXCR2MRGPRX4WDR5LDHA
SCHEMBL23460168 0.85 CXCR2 (0.51) CXCR2PTPN1MRGPRX4MAOBPPARA
SCHEMBL23460002 0.84 CXCR2 (0.50) CXCR2PTPN1MRGPRX4MAOBRXRA
SCHEMBL485359 0.84 CXCR2 (0.52) CXCR2PTPN1MRGPRX4MAOBPPARA
SCHEMBL485537 0.84 CXCR2 (0.76) CXCR2MRGPRX4MAOBDRD4P2RX1
SCHEMBL1598461 0.83 CXCR2 (0.49) CXCR2MRGPRX4WDR5TRPV1LDHA
SCHEMBL484997 0.83 CXCR2 (0.66) CXCR2MRGPRX4PPARGDRD4P2RX1
SCHEMBL25549130 0.83 CXCR2 (0.64) CXCR2PTPN1PPARGTRPV1DRD4
SCHEMBL23460769 0.82 CXCR2 (0.62) CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637414-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-26 US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
WO-2021113808-A1 CFTR-MODULATING ARYLAMIDES GENZYME CORPORATION (US) 2021-06-10 WO disclosed
EP-2040690-B1 INHIBITORS OF CXCR2 SANOFI SA (FR) 2014-08-06 EP disclosed
US-8552033-B2 Inhibitors of CXCR2 SANOFI (FR) 2013-10-08 US disclosed
US-20090215827-A1 INHIBITORS OF CXCR2 SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
EP-2040690-A1 INHIBITORS OF CXCR2 Sanofi-Aventis (FR) 2009-04-01 EP disclosed
WO-2008000407-A1 INHIBITORS OF CXCR2 SANOFI-AVENTIS (FR) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637414-B2 Arylamides and methods of use thereof CFTR, CLIC1, ABCC1 CXCR2 78/4885PTPN1 1271/4885MRGPRX4 1064/4885
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885PTPN1 1876/4885MRGPRX4 886/4885
US-20090215827-A1 INHIBITORS OF CXCR2 CXCR2, CXCR1, CXCR4 CXCR2 1/4885PTPN1 102/4885MRGPRX4 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.